Abstract
The effects of COVID-19 on cancer are substantial, highlighting both novel and existing challenges for health-care systems. We were therefore encouraged to see The Lancet Oncology's call for cancer care to be safeguarded in a postCOVID-19 world.1 We endorse this position for cancer surgery specifically, and propose several recommendations aiming to reduce the so-called collateral damage of COVID-19. The International Cancer Benchmarking Partnership (ICBP) is a global collaboration seeking to compare and improve cancer survival across high income countries.2 Within the ICBP, we came together to provide a voice for the international cancer surgery community.
Original language | English |
---|---|
Pages (from-to) | e339-e340 |
Number of pages | 2 |
Journal | The Lancet Oncology |
Volume | 21 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- COVID-19 (disease)
- cancer
- pandemics